As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.
12 Analysts have issued a Kyverna Therapeutics forecast:
12 Analysts have issued a Kyverna Therapeutics forecast:
Jun '25 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -169 -169 |
39%
39%
|
EBIT (Operating Income) EBIT | -172 -172 |
38%
38%
|
Net Profit | -159 -159 |
36%
36%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company. It develops treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.
Head office | United States |
CEO | Warner Biddle |
Employees | 129 |
Founded | 2018 |
Website | kyvernatx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.